优化扩散加权磁共振成像用于肿瘤三级预防筛查:一项前瞻性离体与在体研究
前瞻性研究纳入54例肿瘤患者共57次腹部MRI检查,在1.5T扫描仪上对比标准EPI-DWI与优化DWI(增加b=1500 s/mm、更高空间分辨率及运动校正等处理)。优化DWI在b=900 s/mm时正常组织信号与背景噪声标准差比值显著升高,图像质量与组织分辨评分显著提高,读者间一致性良好(kappa=0.768)。
要点
- 优化DWI较标准DWI显著提高腹部及腹膜后结构的轮廓锐度和组织分辨(P<0.001)。
- b=900 s/mm时优化DWI正常组织信号/背景噪声标准差比值显著高于标准DWI(P<0.001)。
- 两位独立盲法读者间一致性良好(kappa=0.768;P<0.001)。
核心结论
- 优化DWI协议结合先进处理在定量和定性分析中均获得改善的图像质量,作者建议在肿瘤患者应用DWI前进行肿瘤学优化,以改善筛查和随访检查并更好释放DWI的诊断潜力。
研究设计与样本
- 经机构审查委员会批准的前瞻性研究,包括体模测量、志愿者检查和肿瘤患者腹部检查,纳入54例患者共57次MRI检查(平均年龄58岁,范围21-90岁),在1.5T MRI扫描仪(MAGNETOM Aera;Siemens Healthcare,Erlangen,Germany)上进行,包含标准EPI-DWI(b=50、900 s/mm)和优化DWI(b=0、50、900、1500 s/mm,更高空间分辨率采集及针对腹部的优化处理,包括运动校正、自适应图像组合和背景抑制)。
关键影像表现/征象
- DWI体模显示优化DWI的轮廓锐度和嵌入物分辨更优。
- b=900 s/mm时右/左半腹部正常组织信号与背景噪声标准差比值在优化DWI显著升高(均值71.9±23.5/86.0±43.3)vs 标准DWI(均值51.4±15.4/63.4±36.5;P<0.001)。
- 上腹部和腹膜后结构的轮廓锐度及组织分辨等图像质量参数在优化DWI较标准DWI显著提高(P<0.001)。
诊断标准与关键数值
- 图像质量和组织分辨参数由2名独立盲法读者采用5点Likert量表评分。
- 统计采用Wilcoxon符号秩检验和kappa统计(Bonferroni校正后P<0.05/0.0125)。
- 读者间信度检验显示一致性良好(kappa=0.768;P<0.001)。
临床应用与阅片要点
- 作者建议在肿瘤患者应用DWI前进行肿瘤学优化,以改善筛查和随访检查并更好释放DWI的诊断潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
INTRODUCTION: Diffusion-weighted imaging (DWI) is an important part of oncological magnetic resonance imaging (MRI) examinations, especially for tertiary cancer prevention in terms of early detection of recurrent disease. However, abdominal studies can be challenged by motion artifacts, poor signal-to-noise ratios, and visibility of retroperitoneal structures, which necessitates sequence optimization depending on the investigated region. This study aims at prospectively evaluating an adapted DWI sequence ex vivo and in vivo in oncologic patients undergoing abdominal MRI.
METHODS: This institutional review board-approved, prospective study included phantom measurements, volunteer examinations, and oncologic patient examinations of the abdomen. Fifty-seven MRI examinations in 54 patients (mean age, 58 years; range, 21-90 years) were included into the analysis. The MRI examination were performed at a 1.5 T MRI scanner (MAGNETOM Aera; Siemens Healthcare, Erlangen, Germany) and included both a standard EPI-DWI (s-DWI; b = 50, 900 s/mm) and an adapted DWI (opt-DWI; EPI-DWI with b = 0, 50, 900, 1500 s/mm, acquisition with higher spatial resolution and optimized processing for the abdomen including motion correction, adaptive image combination, and background suppression). For b = 900 s/mm, the ratio of signal intensity in the normal tissue and the standard deviation of the noise in the surrounding air was quantitatively calculated; image quality and tissue differentiation parameters were rated by 2 independent, blinded readers using a 5-point Likert scale. Statistics included Wilcoxon signed-rank test and kappa statistic (P < 0.05/0.0125 after Bonferroni correction).
RESULTS: The DWI phantom demonstrated an optimized contour sharpness and inlay differentiation for opt-DWI. The apparent ratio of normal tissue signal/standard deviation of background noise at b = 900 s/mm of the right/left hemiabdomen was significantly increased in opt-DWI (mean, 71.9 ± 23.5/86.0 ± 43.3) versus s-DWI (mean, 51.4 ± 15.4/63.4 ± 36.5; P < 0.001). Image quality parameters (contour sharpness and tissue differentiation of upper abdominal and retroperitoneal structures) were significantly increased in opt-DWI versus s-DWI (P < 0.001). Interreader reliability test showed good agreement (kappa = 0.768; P < 0.001).
DISCUSSION: This study prospectively evaluated the potential of adapted DWI for screening in tertiary prevention of oncologic patients. An optimized DWI protocol with advanced processing achieved improved image quality in quantitative and qualitative analyses. Oncological optimization of DWI should be performed before its application in cancer patients to improve both screening and follow-up examinations, to better unleash the diagnostic potential of DWI.
引用
- Dreher C, Kuder TA, König F, et al. Modulating Diffusion-Weighted Magnetic Resonance Imaging for Screening in Oncologic Tertiary Prevention: A Prospective Ex Vivo and In Vivo Study. Invest Radiol. 2019. PMID: 31356384. doi:10.1097/RLI.0000000000000596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。